About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Commercialization of drugs by fast tracking is a cause of concern

by Medindia Content Team on February 17, 2006 at 7:38 PM
Font : A-A+

Commercialization of drugs by fast tracking is a cause of concern

A senior doctor has by the means of BMJ raised a serious concern over licensing of new drugs for commercialization purposes.

This has come after natalizumab, a new drug for multiple sclerosis, was approved and thereafter recalled after three months. This was done after three trial patients developed a life threatening condition while being treated.

Advertisement

The drug was licensed by the US Food and Drug Administration in 2004 on the basis of short term results from two unpublished trials. The result was that when tested it was on 28 February 2005, recalled after three trial patients developed progressive multifocal leucoencephalopathy (PML). The result was that in between two of the patients died.

The approval of natalizumab and its recall after three months raises questions about the fast tracking of new drugs by the FDA for commercial licensing. This was brought to the fore by consultant neurologist Abhijit Chaudhuri.

The warning signal is here and it must be paid heed to so that in the future such mistakes are not repeated.

Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Black Tea Protects against Blood Pressure and Heart Diseases
Green Mediterranean Diet may Help Repair Age-Related Brain Damages
Cervical Cancer Awareness Month 2022
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Signature Drug Toxicity Drugs Banned in India 
Recommended Reading
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Drugs Banned in India
Several drugs are either banned or withdrawn after introduction in the market....

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close
ASK A DOCTOR ONLINE
I have read and I do accept terms of use - Telemedicine

Advantage Medindia: FREE subscription for 'Personalised Health & Wellness website with consultation' (Value Rs.300/-)